Neurology on the Hill 2017 #NOH2017

Mark Mintz, MD had an interesting couple of days in Washington D.C. at “Neurology On the Hill 2017” #NOH2017 organized by the American Academy of Neurology!

This annual event brings neurologists from all over the country to “the Hill” in D.C. to meet with top lawmakers and educate them and advocate for important healthcare issues related to neurology.

Mark Mintz, MD meeting with lawmakers at Capitol Hill, including the offices of NJ Senator Cory Booker among others

The AAN 2017 Priority Issues included:
 Access to high quality health care and preventative care through insurance coverage for all, including
those most vulnerable to health care disparities, regardless of pre-existing conditions
 Appropriately value cognitive care services
 Limit administrative requirements and advocate for EHR functionality to ensure that physicians spend as
little time as possible on low-value clerical work, and as much time as possible engaged in direct patient
 Continue efforts to streamline EHR interoperability and reduce data blocking to allow any willing
provider to participate in a qualified clinical data registry
 Improved valuation of patient-centered care setting alternatives including telemedicine and other
innovative care models
 Improve efforts to reduce spending on pharmaceuticals and other key drivers of health care expense
through cost transparency and permit the negotiation of drug costs by Medicare
 Medical liability reforms to reduce the cost of premiums and defensive medicine
 Preservation of the physician-patient relationship including independent medical decision-making and
patient access to needed treatments and education
 Protect access to neurology care in all settings, including small and solo practices

 Support price negotiation for covered Medicare Part D drugs. Price negotiation would allow the government to leverage its purchasing power in an effort to obtain drugs at a lower price, bringing savings to the health care system and consumers.
 Promote transparency in prescription drug pricing. Disclosure of pricing information, including how drugs are priced, the prices paid by insurers, and the prices paid by consumers, would provide important information that could lower costs for patients and the entire health care system.
 Limit direct-to-consumer advertising. Advertisements create demand for unnecessary or inappropriate
medications and marketing costs play a role in escalating drug prices.
 Support drug reimportation for medications of the same high quality. Many specialty drugs are priced
significantly higher in the United States than in other countries. For example, the average monthly price of multiple sclerosis drug Copaxone is 287 percent greater in the United States than Switzerland. Reimportation offers an opportunity to offer lower cost medications.

 Support Senate Appropriations Committee-approved $34.1 billion in NIH funding for FY2017 and the continued annual appropriations to fully fund the NIH Innovation Account, as authorized by the 21st Century Cures Act.

 Improving access to Stroke Telemedicine Care